# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Findings from largest completed study in A-T demonstrated favorable safety profileStudy showed positive effect of EryDex treatm...
Quince Therapeutics (NASDAQ: QNCX) reported quarterly losses of $(0.64) per share. This is a 357.14 percent decrease over losse...
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology d...
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.21) per share. This is a 61.54 percent decrease over losses ...